14.04.2022 - DURHAM, N.C., April 14, 2022 (GLOBE NEWSWIRE) - Heat Biologics, Inc. (“Heat”) (NYSE American: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system and novel biodefense .
StockNews.com initiated coverage on shares of Heat Biologics (NASDAQ:HTBX – Get Rating) in a note issued to investors on Thursday. The firm set a “sell” rating on the biopharmaceutical company’s stock. Other research analysts have also recently issued research reports about the stock. B. Riley cut their target price on shares of Heat Biologics from […]
Jeff Wolf, Chief Executive Officer of Heat, commented, “2021 was a transformative year for Heat as we progress our strategic evolution to become a fully-integrated biopharmaceutical company.